You are now visiting tipharma.com.
On 1 January, 2016, TI Pharma and CTMM merged
to form a new organization called Lygature.
Please note that information on the tipharma.com site has not
been updated since, and is retained as an archive.
For up-to-date information, please visit lygature.org.
Drug discovery and development is associated with high attrition rates largely due to a lack of efficacy and unexpected safety concerns of new drugs. An important question is therefore how to improve the prediction of drug efficacy and safety.
The mechanism-based PK-PD modeling platform 2.0 aims at the development of novel mechanism-based PK-PD modeling concepts for stationary and non-stationary biological systems and builds on the mechanism-based PK-PD modeling platform 1.0. The research program is a systems pharmacology approach which focuses on the development and application of novel mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling concepts. The developed mechanism-based PK-PD models contain expressions to describe, in a quantitative manner, processes on the causal path between plasma concentration and effect. To this end mechanism-based PK-PD modeling utilizes concepts from physiologically-based pharmacokinetic modeling, receptor theory, dynamical systems analysis and disease systems analysis. This research program will yield a mechanism-based PK-PD model library and database which can be used for 1) drug candidate selection, 2) design and evaluation of early 'proof of concept' studies in man, 3) optimization of phase-3 clinical trials, and 4) prediction of long-term outcome of drug treatment. In addition to the generation of models the platform educates a new generation of PK-PD modelers.
Full project title: PK-PD platform 2.0
Start date: 1 November 2012
End date: 1 November 2017
Goal: Develop a mechanism-based PK-PD model library together with a knowledge-based management system to securely store preclinical, clinical and epidemiological data and to support future model-based research in drug discovery and development
Principal investigator: Meindert Danhof
Project size: 9 FTE Partners: Astellas, Erasmus MC, Janssen, Leiden University, Takeda, MSD Oss, University of Groningen
“Running public-private partnerships is a profession by itself. TI Pharma is an excellent example of how you can do this in an effective way.”
Director/Secretary of the Medicines Evaluation Board